Kura Oncology, Inc. (KURA)
Nasdaq · Healthcare · Biotechnology
$10.62−0.28%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $945M
- 52-week range
- $7.36 – $13.90
- 52-week change
- +12.94%
- EPS (trailing)
- −$3.37
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $67.5M (+25.24%)
- Net income
- −$279M
- Operating margin
- −449.9%
- Diluted EPS
- −$3.18
- Free cash flow
- −$70.7M
From the company’s annual report on SEC EDGAR.
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Headquarters: San Diego, United States · 260 employees · kuraoncology.com